nach oben

Erschienen in:

2020 | OriginalPaper | Buchkapitel

6. Evolution of Angioplasty Devices

verfasst von : Martin W. King, Tushar Bambharoliya, Harshini Ramakrishna, Fan Zhang

Erschienen in: Coronary Artery Disease and The Evolution of Angioplasty Devices

Verlag: Springer International Publishing

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

It is estimated that 600,000 to 1 million cardiac catheterizations (CC) are performed annually in the United States. This figure exceeds the number of coronary artery bypass graft procedures (CABG) performed on an annual basis, and is expected to grow annually by about 1–5% in the United States. This chapter discusses the evolution in design and development of angioplasty devices including a list of currently available commercial products and experimental designs under research and development. This will enable the reader to get a glimpse of how the medical device sector is attempting to address this major healthcare problem whose total medical costs are expected to reach $1.1 trillion by 2035.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Treatment of Coronary Artery Disease (CAD)

Bonow RO, Mann DL, Zipes DP, Libby P. Braunwald’s heart disease: a textbook of cardiovascular medicine. Philadelphia: Elsevier/Saunders; 2015.

86.

Slicker K, Lane WG, Oyetayo OO, Copeland LA, Stock EM, Michel JB, et al. Daily cardiac catheterization procedural volume and complications at an academic medical center. Cardiovasc Diagn Ther. 2016;6(5):446–52.CrossRef

87.

Roubin GS. Author. The first balloon-expandable coronary stent: an expedition that changed cardiovascular medicine: a memoir [electronic resource]. St Lucia: University of Queensland Press; 2014.

89.

Singh IM, Holmes DR. Myocardial revascularization by percutaneous coronary intervention: past, present, and the future. Curr Probl Cardiol. 2011;36(10):375–401.CrossRef

90.

Byrne RA, Stone GW, Ormiston J, Kastrati A. Coronary balloon angioplasty, stents, and scaffolds. Lancet. 2017;390(10096):781–92.CrossRef

91.

Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol. 2010;56(10):S1.CrossRef

94.

Shreenivas SS, Sarembock IJ, Kereiakes DJ. Chapter 16 – Stent thrombosis: implications for new stent designs and dual antiplatelet therapy duration. In: Topaz O, editor. Cardiovascular thrombus. San Diego: Academic Press; 2018. p. 225–47.CrossRef

95.

Dubel GJ. Angioplasty balloons, stents, and endografts. Tech Vasc Interv Radiol. 2000;3(4):214–25.CrossRef

96.

Mishra S, Bahl VK. Coronary hardware part 3 – balloon angioplasty catheters. Indian Heart J. 2010;62(4):335–41.

97.

Garramone S. Structure-property relationships in angioplasty balloons. Worcester Polytechnic Institute, Digital WPI; 2001. https://web.wpi.edu/Pubs/ETD/Available/etd-0430101-122300/unrestricted/garramone.pdf

98.

Park S, Bearinger JP, Lautenschlager EP, Castner DG, Healy KE. Surface modification of poly(ethylene terephthalate) angioplasty balloons with a hydrophilic poly(acrylamide-co-ethylene glycol) interpenetrating polymer network coating. J Biomed Mater Res. 2000;53(5):568–76.CrossRef

99.

U.S. Department of Health and Human Services, U. S. Food and Drug Administration. FDA executive summary circulatory system devices panel meeting: paclitaxel-coated drug coated balloon and drug-eluting stent late mortality panel; 2019.

102.

U.S. Department of Health and Human Services, U.S. Food and Drug Administration. Premarket approval (PMA): Lutonix 035 drug coated balloon PTA catheter; 2017.

103.

Hsieh M, Huang Y, Yeh J, Chen C, Chen D, Yang C, et al. Predictors of long-term outcomes after drug-eluting balloon angioplasty for bare-metal stent restenosis. Heart Lung Circ. 2018;27(5):588–94.CrossRef

107.

Li Y, Tellez A, Rousselle SD, Dillon KN, Garza JA, Barry C, et al. Biological effect on drug distribution and vascular healing via paclitaxel-coated balloon technology in drug eluting stent restenosis swine model. Catheter Cardiovasc Interv. 2016;88(1):89–98.CrossRef

108.

Meneguz-Moreno R, Ribamar Costa J, Abizaid A. Drug-coated balloons: Hope or hot air: update on the role of coronary DCB. Curr Cardiol Rep. 2018;20(10):100.CrossRef

109.

Task Fm, Windecker S, Kolh P, Alfonso F, Collet J, Cremer J, et al. 2014 ESC/EACTS guidelines on myocardial revascularization the task force on myocardial revascularization of the European Society of Cardiology (ESC) and The European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–619.CrossRef

110.

Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316(12):701.CrossRef

111.

Pache JÜ, Kastrati A, Mehilli J, Schühlen H, Dotzer F, Hausleiter J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41(8):1283–8.CrossRef

112.

Stefanini GG, Taniwaki M, Windecker S. Coronary stents: novel developments. Heart. 2014;100(13):1051–61.CrossRef

113.

Hanawa T. Materials for metallic stents. J Artif Organs. 2009;12(2):73–9.CrossRef

116.

Purnama A, Hermawan H, Mantovani D. Biodegradable metal stents: a focused review on materials and clinical studies. J Biomater Tissue Eng. 2014 Nov; 4(11):868–74(7).

117.

Schewe S, Glocker DA, Ranade SV. Chapter 4 – Coatings for radiopacity. In: Medical coatings and deposition technologies. Hoboken: Wiley; 2016. p. 115–30.CrossRef

118.

O’Brien B, Carroll W. The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: a review. Acta Biomater. 2009;5(4):945–58.CrossRef

119.

Trevor S, Benjamin H, Daniel RF, Michael F, Yong-Xiang C, Edward O. The evolution of coronary stents: a brief review. Can J Cardiol. 2014;30(1):35–45.CrossRef

120.

Khan W, Farah S, Domb AJ. Drug eluting stents: developments and current status. J Control Release. 2012;161(2):703–12.CrossRef

121.

U.S. Department of Health and Human Services, U. S. Food and Drug Administration. Establishment registration & device listing; 2019.

122.

Neumann F, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2018;2018:ehy394.

123.

Bønaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygård O, et al. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375(13):1242–52.CrossRef

124.

Zheng F, Xing S, Gong Z, Xing Q. Five-year outcomes for first generation drug-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2014 Jun;23(6):542–8.CrossRef

125.

U.S. Department of Health and Human Services, U. S. Food and Drug Administration. Premarket approval (PMA): Resolute onyx zotarolimus-eluting coronary stent system; 2017.

126.

Whitbeck MG, Applegate RJ. Second generation drug-eluting stents: a review of the everolimus-eluting platform. Clin Med Insights Cardiol. 2013;7:115–26.CrossRef

127.

Health, Center for Devices and Radiological. Recently-approved devices – EluNIR® ridaforolimus eluting coronary stent system – P170008; 2017.

128.

Partida RA, Yeh RW. Contemporary drug-eluting stent platforms. Interv Cardiol Clin. 2016;5(3):331–47.

129.

Alahmar A, Gershlick A. Drug-eluting stents—issues and developments. US Cardiol Rev. 2009;6(2):87–96.

130.

Park DS, Bae I, Jeong MH, Lim K, Hong YJ, Shim JW, et al. Anti-restenotic and anti-thrombotic effect of polymer-free N-TiO2 film-based tacrolimus-eluting stent in a porcine model. Mater Today Commun. 2020;22:100777.CrossRef

131.

Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis. Circulation. 2007;115(8):1051.CrossRef

134.

Zhu S, Viswambharan H, Gajanayake T, Ming X, Yang Z. Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells. BMC Cardiovasc Disord. 2005;5(1):22.CrossRef

135.

Cho Y, Yang H, Park K, Chung W, Choi D, Seo W, et al. Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction. J Am Coll Cardiol Intv. 2010;3(5):498.CrossRef

136.

Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96(2):636–45.CrossRef

137.

Busch R, Strohbach A, Peterson S, Sternberg K, Felix S. Parameters of endothelial function are dependent on polymeric surface material. Biomed Tech (Berl). 2013; 58(1). https://doi.org/10.1515/bmt-2013-4053

138.

Busch R, Strohbach A, Rethfeldt S, Walz S, Busch M, Petersen S, et al. New stent surface materials: the impact of polymer-dependent interactions of human endothelial cells, smooth muscle cells, and platelets. Acta Biomater. 2014;10(2):688–700.CrossRef

139.

Akinapelli A, Chen JP, Roy K, Donnelly J, Dawkins K, Huibregtse B, et al. Current state of bioabsorbable polymer-coated drug-eluting stents. Curr Cardiol Rev. 2016;13(2):139–54.

140.

Ranade SV, Udipi Kishore, Glocker DA. Chapter 3 – Drug delivery coatings for coronary stents. In: Medical coatings and deposition technologies. Hoboken: Wiley; 2016. p. 75–114.CrossRef

141.

Kang S, Park KW, Kang D, Lim W, Park KT, Han J, et al. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J. 2014;35(17):1147–58.CrossRef

143.

van der Heijden KMM, Zocca P, GAJ J, Schotborgh CE, Roguin A, et al. Bioresorbable polymer-coated orsiro versus durable polymer-coated resolute onyx stents (BIONYX): rationale and design of the randomized TWENTE IV multicenter trial. Am Heart J. 2018;198:25–32.CrossRef

144.

Lam MK, Sen H, Tandjung K, van Houwelingen KG, de Vries AG, Danse PW, et al. Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): rationale and study design of the randomized TWENTE III multicenter trial. Am Heart J. 2014;167(4):445–51.CrossRef

145.

Garg S, Serruys PW. Coronary stents looking forward. J Am Coll Cardiol. 2010;56(10):S43–78.CrossRef

146.

Grube E, Schofer J, Hauptmann KE, Nickenig G, Curzen N, Allocco DJ, et al. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer: 9-month outcomes with the JACTAX HD stent. J Am Coll Cardiol Intv. 2010;3(4):431–8.CrossRef

147.

Nogic J, McCormick LM, Francis R, Nerlekar N, Jaworski C, West NEJ, et al. Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents. J Cardiol. 2018;71(5):435–43.CrossRef

148.

Baquet M, Jochheim D, Mehilli J. Polymer-free drug-eluting stents for coronary artery disease. J Interv Cardiol. 2018;31(3):330–7.CrossRef

150.

Lee JH, Kim ED, Jun EJ, Yoo HS, Lee JW. Analysis of trends and prospects regarding stents for human blood vessels. Biomater Res. 2018;22:8.CrossRef

151.

De Luca G, Smits P, Hofma SH, Di Lorenzo E, Vlachojannis GJ, Van’t Hof AWJ, Arnoud WJ, et al. Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Int J Cardiol. 2017;244:121–7.CrossRef

152.

Kawakami R, Hao H, Imanaka T, Shibuya M, Ueda Y, Tsujimoto M, et al. Initial pathological responses of second-generation everolimus-eluting stents implantation in Japanese coronary arteries: comparison with first-generation sirolimus-eluting stents. J Cardiol. 2018;71(5):452–7.CrossRef

153.

Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig lecture ESC 2014. Eur Heart J. 2015;36(47):3320.CrossRef

159.

Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD, Virmani R. The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol. 2012;9(8):439–53.CrossRef

160.

Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36(32):2147–59.CrossRef

161.

Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J. 2009 Apr;73(4):615–21.CrossRef

162.

Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation. 2005;111(7):926–31.CrossRef

163.

Meyers SR, Kenan DJ, Khoo X, Grinstaff MW. A bioactive stent surface coating that promotes endothelialization while preventing platelet adhesion. Biomacromolecules. 2011;12(3):533–9.CrossRef

164.

Butzal M, Loges S, Schweizer M, Fischer U, Gehling UM, Hossfeld DK, et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res. 2004 Oct 15;300(1):65–71.CrossRef

165.

Im SH, Jung Y, Kim SH. Current status and future direction of biodegradable metallic and polymeric vascular scaffolds for next-generation stents. Acta Biomater. 2017;60:3–22.CrossRef

167.

Dave B. Bioresorbable scaffolds: current evidences in the treatment of coronary artery disease. J Clin Diagn Res. 2016 Oct;10(10):OE01–7.

168.

Borhani S, Hassanajili S, Ahmadi Tafti SH, Rabbani S. Cardiovascular stents: overview, evolution, and next generation. Prog Biomater. 2018;7(3):175–205.CrossRef

170.

Hideo-Kajita A, Wopperer S, Seleme VB, Ribeiro MH, Campos CM. The development of magnesium-based resorbable and iron-based biocorrodible metal scaffold technology and biomedical applications in coronary artery disease patients. Appl Sci (Basel). 2019 Sep 1;9(17):3527.CrossRef

171.

Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for reendothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv. 2011;4(10):1057–66.CrossRef

172.

McGonigle J, Webster TJ, Bhardwaj G, Glocker DA, Ranade SV. Chapter 5 – Biocompatibility and medical device coatings. In: Medical coatings and deposition technologies. Hoboken: Wiley; 2016. p. 131–80.CrossRef

173.

Wu D, Yu M, Gao H, Zhang L, Song F, Zhang X, et al. Polymer-free versus permanent polymer drug eluting stents in coronary artery disease: a meta-analysis of 10 RCTs with 6575 patients. Chronic Dis Transl Med. 2015;1(4):221–30.CrossRef

174.

Richards CN, Schneider PA. Will mesh-covered stents help reduce stroke associated with carotid stent-angioplasty? Semin Vasc Surg. 2017;30(1):25–30.CrossRef

176.

Yang Z, Tu Q, Wang J, Huang N. The role of heparin binding surfaces in the direction of endothelial and smooth muscle cell fate and re-endothelialization. Biomaterials. 2012;33(28):6615–25.CrossRef

187.

McKittrick CM, Cardona MJ, Black RA, McCormick C. Development of a bioactive polymeric drug eluting coronary stent coating using electrospraying. Ann Biomed Eng. 2020;48(1):271–81.CrossRef

Titel: Evolution of Angioplasty Devices
verfasst von: Martin W. King
Tushar Bambharoliya
Harshini Ramakrishna
Fan Zhang
Verlag: Springer International Publishing
Buch: Coronary Artery Disease and The Evolution of Angioplasty Devices
Print ISBN: 978-3-030-42442-8

Electronic ISBN: 978-3-030-42443-5

Copyright-Jahr: 2020
DOI: https://doi.org/10.1007/978-3-030-42443-5_6

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht